IN2014DN01791A - - Google Patents

Info

Publication number
IN2014DN01791A
IN2014DN01791A IN1791DEN2014A IN2014DN01791A IN 2014DN01791 A IN2014DN01791 A IN 2014DN01791A IN 1791DEN2014 A IN1791DEN2014 A IN 1791DEN2014A IN 2014DN01791 A IN2014DN01791 A IN 2014DN01791A
Authority
IN
India
Prior art keywords
prevention
treatment
invention concerns
receptor antagonists
ampa receptor
Prior art date
Application number
Other languages
English (en)
Inventor
Klaus Kucher
Donald Johns
George Imbert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN01791A publication Critical patent/IN2014DN01791A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1791DEN2014 2011-09-07 2011-09-07 IN2014DN01791A (instruction)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
IN2014DN01791A true IN2014DN01791A (instruction) 2015-05-15

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1791DEN2014 IN2014DN01791A (instruction) 2011-09-07 2011-09-07

Country Status (10)

Country Link
EP (1) EP2753331A1 (instruction)
JP (1) JP2014525474A (instruction)
KR (1) KR20140071405A (instruction)
CN (1) CN103889427A (instruction)
AU (1) AU2011376333A1 (instruction)
BR (1) BR112014005210A2 (instruction)
CA (1) CA2846503A1 (instruction)
IN (1) IN2014DN01791A (instruction)
MX (1) MX2014002693A (instruction)
WO (1) WO2013036224A1 (instruction)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
WO2005044266A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
CA2549969A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
JP2007509934A (ja) 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキン類iii
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
JP2009519986A (ja) 2005-12-20 2009-05-21 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体のモジュレーターとしてのニコチン酸誘導体
ES2753141T3 (es) * 2009-11-03 2020-04-07 Lupin Ltd Formulación de liberación modificada de lacosamida

Also Published As

Publication number Publication date
AU2011376333A1 (en) 2014-03-13
CN103889427A (zh) 2014-06-25
MX2014002693A (es) 2014-06-04
JP2014525474A (ja) 2014-09-29
WO2013036224A1 (en) 2013-03-14
CA2846503A1 (en) 2013-03-14
BR112014005210A2 (pt) 2017-03-21
KR20140071405A (ko) 2014-06-11
EP2753331A1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
GB201017345D0 (en) Receptor antagonists
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
HK1209159A1 (en) Methods of decellularizing bone
HUE047410T2 (hu) 4H-Pirazolo[1,5-a]benzimidazol vegyület analógjai, mint PARP inhibitorok
ZA201501262B (en) 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders
PH12018500282A1 (en) Cgrp receptor antagonists
FR2979931B1 (fr) Potelet de garde-corps ou d'echafaudage equipe d'un bloqueur perfectionne
PL2807170T3 (pl) Limonoidy fragmaliny do leczenia dysfunkcji seksualnych
EP2771346A4 (en) ISOXAZOLOPYRIDIN-orexin
IN2014KN02993A (instruction)
HUE045270T2 (hu) FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
AP2012006630A0 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
IN2014DN00254A (instruction)
IN2014DN01791A (instruction)
SG11202111525XA (en) Stable targeted integration
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
GB201012359D0 (en) Invention 6.5.10
WO2013130501A8 (en) Bivalent ampa receptor positive allosteric modulators
FR2996871B1 (fr) Dispositif de correction de la courbure d'une dalle de plancher
IN2012DN00235A (instruction)